39 completed, 10 terminated, 7 recruiting, 7 unknown. 75 Phase 1, 40 Phase 2.
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
| Quercetin Dyskeratosis Congenita (DC)/Telomere Biology Disorders (TBD) Quercetin - Dyskeratosis Congenita, Telomere Disease | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 12 | 2026-05-29 | 2026-09-10 |
| GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) - RDEB, Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | CHU de Quebec-Universite Laval | 9 | 2026-01-07 | 2026-03-18 |
| Nucleoside Therapy in Patients With Telomere Biology Disorders deoxycytidine, deoxythymidine - Telomere Biology Disorders, Dyskeratosis Congenita | Phase 1 | Recruiting | Suneet Agarwal | 36 | 2025-09-29 | 2026-08-04 |
| Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa Immunoglobulin G - Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Recruiting | M. Peter Marinkovich | 8 | 2025-08-04 | 2026-05-05 |
| Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases Subtenon Injection of Autologous Platelet-Rich Plasma - Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Active not recruiting | Rubens Camargo Siqueira | 30 | 2025-01-04 | 2026-07-01 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 BCX17725, Placebo - Netherton Syndrome | Phase 1 | Active not recruiting | BioCryst Pharmaceuticals | 76 | 2024-09-26 | 2026-11-06 |
| MSC EVs in Dystrophic Epidermolysis Bullosa AGLE-102 - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | Aegle Therapeutics | 8 | 2024-08-13 | 2025-06-25 |
| Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome ATR12-351 - Netherton Syndrome | Phase 1 | Completed | Azitra Inc. | 6 | 2024-06-16 | 2026-07-29 |
| Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops) - Junctional Epidermolysis Bullosa, Epidermolysis Bullosa (EB) | Phase 1 | Active not recruiting | Fundación DEBRA Chile, Niños Piel de Cristal | 20 | 2024-05-07 | 2025-12-31 |
| Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts | Phase 1 | Terminated | Washington University School of Medicine | 6 | 2024-03-14 | 2026-09-03 |
| Fractional Co2 Laser Versus Microbotox Injection in the Treatment of Wide Facial Pores: A Split Face Comparative Study microbotox, fractional carbon dioxide laser - Skin Abnormalities | Phase 1 | Unknown | Assiut University | 21 | 2024-02-01 | 2023-12-27 |
| Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa Ev.FV 1.0 x 1011 par/ml - Dystrophic Epidermolysis Bullosa, Wound Heal | Phase 1 / Phase 2 | Recruiting | Isfahan University of Medical Sciences | 20 | 2024-01-09 | 2025-11-17 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency INZ-701 - Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 1 | Terminated | Inozyme Pharma | 9 | 2023-06-25 | 2026-10-15 |
| Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene PTW-002 10 mg/g gel, Placebo - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | Phoenicis Therapeutics | 8 | 2023-04-30 | 2023-03-31 |
| Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC KM-001 cream 1% 12 weeks treatment., Physical Examination, Vital Signs - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 18 | 2023-03-06 | 2025-01-15 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
Showing 20 of 75. Sign in to see all of them.
Epidermolysis Bullosa Dystrophica (25) · Epidermolysis Bullosa (15) · Netherton Syndrome (9) · Port-Wine Stain (8) · Pachyonychia Congenita (6) · Dyskeratosis Congenita (5) · Epidermolysis Bullosa, Junctional (5) · Skin Diseases (4) · Epidermolysis Bullosa Simplex (3) · Fanconi Anemia (3) · Pseudoxanthoma Elasticum (3) · Skin Diseases, Genetic (3) · Anemia, Diamond-Blackfan (2) · Anemia, Sickle Cell (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (74) · Skin and Connective Tissue Diseases (74) · Congenital Abnormalities (71) · Skin Diseases (71) · Genetic Diseases, Inborn (63) · Skin Diseases, Genetic (61) · Skin Diseases, Vesiculobullous (34) · Connective Tissue Diseases (32) · Collagen Diseases (25) · Epidermolysis Bullosa (20) · Abnormalities, Multiple (18) · Infant, Newborn, Diseases (14) · Keratosis (13) · Ichthyosis (11)
Gentamicins (6) · Hematologic Tests (2) · Lasers, Dye (2) · Pain Measurement (2) · Physical Examination (2) · Ranibizumab (2) · Saline Solution (2) · Therapeutics (2) · Urinalysis (2) · Vital Signs (2) · cyclic adenosine-5'-trimetaphosphate (2) · ADI PEG20 (1) · ADX-629 (1) · Abatacept (1) · Angiogenesis Inhibitors (1)
University of California, Irvine (8) · University of Southern California (5) · Daiichi Sankyo (3) · Holostem s.r.l. (2) · Inozyme Pharma (2) · King's College London (2) · M. Peter Marinkovich (2) · Orvida Pharma (formerly Kamari Pharma) (2) · Phoenicis Therapeutics (2) · Abeona Therapeutics, Inc (1) · Aegle Therapeutics (1) · Anterogen Co., Ltd. (1) · Assiut University (1) · AstraZeneca (1) · Azitra Inc. (1)
United States (47) · United Kingdom (8) · France (6) · Austria (5) · Germany (3) · Spain (3) · Canada (2) · Netherlands (2) · South Korea (2) · Sweden (2) · Australia (1) · Brazil (1) · Chile (1) · Iran (1) · Israel (1)
David Woodley, MD (2) · Jakub Tolar, MD, PhD (2) · Johann W. Bauer, MD (2) · John S Nelson, M.D,PhD (2) · Matt P Marinkovich, MD (2) · Michele De Luca, MD/Professor (2) · Albert C Yan, MD (1) · Amy Paller (1) · Bernard Cohen, MD (1) · Colin A Sieff, MB.BCh (1) · Dalia A Ahmed, professor (1)
PMID 35234826, PMID 20083693, PMID 22517769, PMID 24329107, PMID 27802546, PMID 28691931, PMID 31167965, PMID 31215818, PMID 31578311, PMID 33011075, PMID 33491668, PMID 33750925, PMID 34665781, PMID 35347281, PMID 36253825, PMID 36813496, PMID 36868990, PMID 39627888, PMID 41327356, PMID 41645556, PMID 42164509, PMID 42193355
2016 (1), 2017 (1), 2025 (1), P30CA015704 (1), R01AR055914 (1), UL1RR024150 (1), UM1CA154967 (1)